Biovitrum and Symphogen enter into a collaboration around recombinant polyclonal antibodies
10. Mai 2004 05:09 ET
|
Biovitrum
STOCKHOLM, Sweden, May 10, 2004 (PRIMEZONE) -- Biovitrum AB and The Danish biotech company Symphogen A/S have signed a fee-for-service agreement, which involves process development and production of...
Biovitrum licenses a project in metabolic diseases from Synaptic, a wholly owned subsidiary of Lundbeck
28. April 2004 05:03 ET
|
Biovitrum
STOCKHOLM, Sweden, April 28, 2004 (PRIMEZONE) -- Biovitrum AB has agreed with Synaptic Pharmaceutical Corporation to license a novel and competitive project within the field of metabolic diseases....
Biovitrum signs agreement to become sole supplier of Wyeth's Hemophilia drug ReFacto
26. Januar 2004 04:12 ET
|
Biovitrum
STOCKHOLM, Sweden, Jan. 26, 2004 (PRIMEZONE) -- Biovitrum has signed an agreement with Wyeth (NYSE: WYE) to be the sole supplier of its recombinant factor VIII drug ReFacto(R), for the treatment of...
Tripos and Biovitrum Announce Successful Chemistry Partnership Results and new Informatics Research Collaboration
08. Dezember 2003 02:13 ET
|
Biovitrum
STOCKHOLM, Sweden and ST. LOUIS, Dec. 08, 2003 (PRIMEZONE) -- Tripos, Inc. (Nasdaq:TRPS) and the Swedish biotech company Biovitrum today announced positive results from the companies' discovery...
Biovitrum creates new business unit and secures multi-year agreement with Amgen
28. Oktober 2003 05:34 ET
|
Biovitrum
STOCKHOLM, Sweden, Oct. 28, 2003 (PRIMEZONE) -- Biotechnology company Biovitrum, has established a new business unit, Biovitrum Biopharmaceuticals, with the purpose of strengthening its position as a...
Amgen and Biovitrum sign license agreement for innovative treatment of type 2 diabetes and other metabolic disorders
08. September 2003 09:07 ET
|
Biovitrum
STOCKHOLM, Sweden, Sept. 08, 2003 (PRIMEZONE) -- Amgen Inc. (Nasdaq:AMGN) and Biovitrum AB today announced that they have signed a multifaceted agreement under which Amgen receives exclusive rights...
Biovitrum and GlaxoSmithKline to Focus Efforts
22. Mai 2003 05:53 ET
|
Biovitrum
STOCKHOLM, Sweden, May 22, 2003 (PRIMEZONE) -- Biovitrum AB today announced that Biovitrum and GlaxoSmithKline (Other OTC:GLAXF) have jointly decided to focus their efforts on the development of...
Biovitrum Initiates Clinical Phase IIb Study of Anti-Obesity Treatment
07. April 2003 04:04 ET
|
Biovitrum
STOCKHOLM, Sweden, April 7, 2003 (PRIMEZONE) -- Biovitrum today announced the start of a clinical Phase IIb study of the anti-obesity compound BVT.933 (GW876167), a 5-HT2C receptor agonist for the...
Biovitrum Initiates Phase II Study with its Diabetes Candidate Drug BVT.3498
25. März 2003 04:06 ET
|
Biovitrum
STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. The primary end-point of the...
Biovitrum Signs Agreement with Lundbeck to Produce Protein Therapeutics
14. Januar 2003 04:08 ET
|
Biovitrum
STOCKHOLM, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Biovitrum AB today announces a commission agreement with the Danish pharmaceutical company Lundbeck A/S for the production of a protein...